首页 | 本学科首页   官方微博 | 高级检索  
     

促肝细胞生成素联合阿拓莫兰治疗失代偿期肝硬化的临床研究(附45例分析)
引用本文:朱金照,张志坚. 促肝细胞生成素联合阿拓莫兰治疗失代偿期肝硬化的临床研究(附45例分析)[J]. 福建医药杂志, 2003, 25(3): 13-14
作者姓名:朱金照  张志坚
作者单位:南京军区福州总医院消化内科,350025
摘    要:
目的 观察促肝细胞生成素与阿拓莫兰联合治疗失代偿期肝硬化的临床疗效。方法 45例失代偿期肝硬化患者随机分为治疗组20例及对照组25例,治疗组应用促肝细胞生成素80mg及阿拓莫兰1200mg静脉滴注,对照组采用阿拓莫兰1200mg静脉滴注,两组同时给予支持等综合治疗,疗程共4周,观察治疗后患者症状、体征及肝功能等变化。结果 疗程结束后治疗组患者症状、体征及肝功能状况的改善均明显优于对照组。结论 促肝细胞生成素与阿拓莫兰联合治疗失代偿期肝硬化有较好疗效。

关 键 词:失代偿期肝硬化 促肝细胞生成素 阿拓莫兰 治疗 疗效
文章编号:1002-2600(2003)03-0013-02

The effect of prohepatocyte growth factor (PHGF) and atuomulan on hepatic cirrhosis with disfunction
Zhu Jinzhao,Zhang Zhijian. The effect of prohepatocyte growth factor (PHGF) and atuomulan on hepatic cirrhosis with disfunction[J]. Fujian Medical Journal, 2003, 25(3): 13-14
Authors:Zhu Jinzhao  Zhang Zhijian
Affiliation:Zhu Jinzhao,Zhang Zhijian.Department of gastroenterology,Fuzhou General Hospital of Nanjing Army Command,Fuzhou 350025,China
Abstract:
Objective To observe the effect of prohepatocyte growth factor(PHGF)and atuomulan on hepatic cirrhosis with disfunction.Methods 45 patients with hepatic cirrhosis were randomly divided into treatment group(n=20)and control group(n=25),PHGF 80mg and atuomulan 1200mg were used to intervenous drip in treatment group and atuomulan 1200mg was used to intervenous drip in control group for 4 weeks,while two groups were given multiple treatment,observing the changes of symptoms,signs and hepatic function after treatment.Results The improvement of symptoms,signs and hepatic function in treatment group was superior to control group.Conclusion The union application of PHGF and atuomulan has a good effect on hepatic cirrhosis with disfunction.
Keywords:Hepatic cirrhosis  PHGF  Atuomulan
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号